₹1,012.55-7.20 (-0.71%)
20-Dec-2024₹1,013.30-3.85 (-0.38%)
20-Dec-2024BSE : 543322
NSE : GLS
Sector : Health care
ISIN Code : INE03Q201024
Last Updated: 20-Dec-2024
Market Cap (₹ Cr) | 12,409 |
Traded Value (₹ Cr) | 0.44 |
Volume (Shares) | 4,341 |
Face Value (₹) | 2 |
52-Week High (₹) | 1,335.00 |
52-Week High Date | 16-Sep-2024 |
52-Week Low (₹) | 627.25 |
52-Week Low Date | 21-Dec-2023 |
All Time High (₹) | 1,335.00 |
All Time High Date | 16-Sep-2024 |
All Time Low (₹) | 369.00 |
All Time Low Date | 22-Feb-2023 |
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 12,418 |
EPS - TTM (₹) [C] | 28.69 |
P/E Ratio (X) [C] | 35.32 |
Face Value (₹) | 2 |
Latest Dividend (%) | 1,125.00 |
Latest Dividend Date | 17-Oct-2023 |
Dividend Yield (%) | 4.82 |
Book Value Share (₹) [C] | 147.95 |
P/B Ratio (₹) [C] | 6.85 |
Scheme Name | Amount Invested (₹ Cr) | No Of Shares | Net Asset (%) |
---|---|---|---|
Quant Flexi Cap Fund - Direct (IDCW) | 117.98 | 10,88,244 | 1.61 |
Quant Flexi Cap Fund - Direct (G) | 117.98 | 10,88,244 | 1.61 |
Quant Flexi Cap Fund (G) | 117.98 | 10,88,244 | 1.61 |
Quant Flexi Cap Fund (IDCW) | 117.98 | 10,88,244 | 1.61 |
Quant Business Cycle Fund - Direct (IDCW) | 53.93 | 4,97,480 | 3.51 |
Quant Business Cycle Fund - Direct (G) | 53.93 | 4,97,480 | 3.51 |
Quant Business Cycle Fund - Regular (G) | 53.93 | 4,97,480 | 3.51 |
Quant Business Cycle Fund - Regular (IDCW) | 53.93 | 4,97,480 | 3.51 |
ICICI Pru P.H.D Fund - Direct (G) | 52.48 | 4,84,063 | 1.04 |
ICICI Pru P.H.D Fund - Direct (IDCW) | 52.48 | 4,84,063 | 1.04 |
Load more
Today's Low/High (₹) | 1,005.50 1,030.00 |
Week Low/High (₹) | 999.95 1,055.00 |
Month Low/High (₹) | 999.95 1,130.00 |
Year Low/High (₹) | 627.15 1,335.00 |
All time Low/High (₹) | 369.00 1,335.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -0.55% | -0.48% | -4.98 | -4.77% |
1 Month | -6.52% | -6.43% | 0.60 | 0.29% |
3 Month | -11.94% | -12.03% | -7.69 | -8.54% |
6 Month | 20.74% | 20.68% | 0.73 | 0.09% |
1 Year | 60.54% | 59.98% | 10.69 | 11.52% |
3 Year | 68.71% | 68.87% | 39.80 | 41.97% |
Managing Director & CEO : Yasir Yusufali Rawjee
Executive Director : Vinod Naik
Independent Non Exe. Director : Manju Agarwal
Independent Non Exe. Director : Taruvai Laxminarayanan Easwar
Chairman (Non-Executive) : HIREN KARSANBHAI PATEL
Independent Director : KAUSHIKBHAI NANDUBHAI PATEL
Independent Director : VIJAYKUMAR RATILAL SHAH
Independent Director : Savan Godialwala
Company Sec. & Compli. Officer : Rudalf Corriea
Registered Office: Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth,Solapur,Maharashtra-413213 Ph: 91-2189-234456/234246
1. What's the Glenmark Life Sciences Ltd share price today?
Glenmark Life Sciences Ltd share price was Rs 1,012.55 at close on 20th Dec 2024. Glenmark Life Sciences Ltd share price was down by 0.71% from the previous closing price of Rs 1,019.75. Glenmark Life Sciences Ltd share price trend:
2. How can I quickly analyse the performance of the Glenmark Life Sciences Ltd stock?
The performance of the Glenmark Life Sciences Ltd stock can be quickly analysed on the following metrics:
3. What is the market cap of Glenmark Life Sciences Ltd?
Glenmark Life Sciences Ltd has a market capitalisation of Rs 12,409 crore.
4. What is Glenmark Life Sciences Ltd's 52-week high/low share price?
The Glenmark Life Sciences Ltd’s 52-week high share price is Rs 1,335.00 and 52-week low share price is Rs 627.25.
5. Is the Glenmark Life Sciences Ltd profitable?
On a consolidated basis, Glenmark Life Sciences Ltd reported a profit of Rs 95.32 crore on a total income of Rs 515.41 crore for the quarter ended 2024. For the year ended Sep 2024, Glenmark Life Sciences Ltd had posted a profit of Rs 95.32 crore on a total income of Rs 515.41 crore.
6. Which are Glenmark Life Sciences Ltd’s peers in the Health care sector?
Glenmark Life Sciences Ltd’s top 5 peers in the Health care sector are Granules India, Sanofi India, Marksans Pharma, Glenmark Life, Sanofi Consumer, Blue Jet Health, Orchid Pharma.
7. Who owns how much in Glenmark Life Sciences Ltd?
Key changes to the Glenmark Life Sciences Ltd shareholding are as follows: